Complement Factors for Diagnosis of Low-Grade Infections in a Human Subject

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent describes a method and biomarker for diagnosing low-grade infections in humans using complement system factors, particularly complement factor C9. By detecting the presence of these complement proteins in tissue or blood samples with methods such as ELISA or immunohistochemistry, the invention enables specific identification of low-grade infections, which are otherwise hard to diagnose, especially after surgeries involving implants.

Use CasesContent extracted from patent full text and abstract with AI.

• Early diagnosis of low-grade infections after implant surgeries (e.g., shoulder or hip replacements)
• Discriminating between aseptic and septic implant loosening
• Supporting clinical decisions for early intervention and targeted therapy for infections
• Screening of patients with unexplained symptoms or implant pain to rule out low-grade infection
• Research tool for understanding inflammatory responses in various forms of implant-related complications

BenefitsContent extracted from patent full text and abstract with AI.

• Enables fast and highly specific diagnosis of low-grade infections, particularly with complement factor C9 showing 100% specificity in tested scenarios
• Reduces the need for unnecessary surgical revisions by identifying infections early
• Improves patient outcomes by allowing for targeted treatment before severe complications develop
• Outperforms traditional infection markers like CRP, WBC, or α-defensin in sensitivity and specificity for low-grade infections
• Applicable to multiple types of implants and human tissues, extending its clinical utility

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The invention relates to a biomarkerfor diagnosis of low-grade infections in a human subject and a method for diagnosis of low-grade infections in a human subject.